← Back to Search

Cancer Vaccine

GRT-C901 for Non-Small Cell Lung Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Gritstone Bio, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

NSCLC who are planned for or have received no more than 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy (note: patients who have received anti-PD-(L)1 monotherapy are eligible)

mUC who are planned for or have received no more than 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 4 years

Awards & highlights

Study Summary

This trial is testing a new cancer vaccine in combination with two immunotherapy drugs. The goal is to see if it is safe and effective in treating patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.

Eligible Conditions

Non-Small Cell Lung Cancer
Colorectal Cancer
Gastroesophageal Adenocarcinoma
Bladder Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

Patients with non-small cell lung cancer who have only received one cycle of chemotherapy are eligible for this study.

Select...

Patients who have only received one cycle of chemotherapy are classified as having mUC.

Select...

The following text discusses how a disease is measured according to RECIST v1.1

Select...

You are at least 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902

Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

Objective Response Rate (ORR) in Phase 2 using RECIST v1.1

Secondary outcome measures

Clinical benefit rate (using RECIST v1.1)

Duration of response (DOR) using RECIST v1.1

Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Phase 2 CohortsExperimental Treatment4 Interventions

GRT-C901 GRT-R902 nivolumab ipilimumab

Group II: Phase 1Experimental Treatment4 Interventions

GRT-C901 GRT-R902 nivolumab ipilimumab

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ipilimumab

FDA approved

GRT-C901

2019

Completed Phase 2

~30

GRT-R902

2019

Completed Phase 2

~30

Nivolumab

FDA approved

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gritstone Bio, Inc.Lead Sponsor

5 Previous Clinical Trials

894 Total Patients Enrolled

Gritstone Oncology, Inc.Lead Sponsor

5 Previous Clinical Trials

894 Total Patients Enrolled

Gritstone bio, Inc.Lead Sponsor

8 Previous Clinical Trials

1,318 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the capacity of participants in this trial?

"This specific trial is no longer actively looking for participants as the last edit was made on August 31st 2021. However, there are still 2129 studies that seek to understand gastroesophageal reflux disease and 765 trials related to GRT-C901 currently recruiting."

Answered by AI

What maladies can be alleviated by GRT-C901?

"GRT-C901 is often given to patients who have previously attempted anti-angiogenic therapy, as well as those with a variety of other maladies like melanoma and squamous cell carcinoma."

Answered by AI

What past research has been conducted utilizing GRT-C901?

"As of today, there are 765 active clinical trials researching GRT-C901. Of those experiments, 86 have advanced to Phase 3 and the vast majority (42755) are taking place in Pittsburgh, Pennsylvania."

Answered by AI

How widespread is the availability of this trial?

"This clinical trial is available in 10 different locations, such as The University of Chicago (Chicago), Columbia University Medical Center (New york) and Mayo Clinic Arizona (Phoenix)."

Answered by AI

Are there still openings for individuals to participate in this experiment?

"This clinical trial is now defunct, as the last update was posted on August 31st 2021. For those seeking alternate studies, there are currently 2129 trials actively recruiting patients with gastroesophageal reflux disease and 765 trials for GRT-C901 that require participants."

Answered by AI